SCOPUS 정보 검색 플랫폼

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 1, 2001, Pages 102-105

Technology evaluation: BLP-25, Biomira Inc

(1) Morse, M A a

a DUKE UNIVERSITY MEDICAL CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLP 25; CANCER VACCINE; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; LIPOSOME; MUCIN; PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL SECRETION; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOPERATION; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; ERYTHEMA; FATIGUE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INJECTION SITE; KILLER CELL; LICENCE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MOLECULE; MOUSE; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; SURVIVAL TIME; UNITED STATES;

AMINO ACID SEQUENCE; BIOTECHNOLOGY; CA-15-3 ANTIGEN; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 0035113091 PISSN: 14648431 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (19)

References (24)

1
- 0005909919
- 274576 Biomira Inc: Prestigious journal publishes Biomira findings. Press release 12 January
- (1998)

2
- 0005910767
- 278438 Biomira Inc: Biomira presents additional MUC-1 data at vaccine conference. Press release 18 February
- (1998)

3
- 0031457133
- Antibody and T-cell responses of patients with adenocarcinoma immunized with mannan-MUC-1 fusion protein
- 284018
- (1997) J Clin Invest , vol.100 , Issue.11 , pp. 2783-2792
- Karanikas, V.¹ Hwang, L.A.² Pearson, J.³ Ong, C.S.⁴ Apostolopoulos, V.⁵ Vaughan, H.⁶ Xing, P.X.⁷ Jamieson, G.⁸ Pietersz, G.⁹ Tait, B.¹⁰ Broadbent, R.¹¹ Thynne, G.¹² McKenzie, I.F.¹³

4
- 0032545730
- Immunogenicity and antitumor activity of a liposomal MUC-1 peptide-based vaccine
- 284030
- (1998) Int J Cancer , vol.75 , Issue.2 , pp. 295-302
- Samuel, J.¹ Budzynski, W.A.² Reddish, M.A.³ Ding, L.⁴ Zimmermann, G.L.⁵ Krantz, M.J.⁶ Koganty, R.R.⁷ Longenecker, B.M.⁸

5
- 0032503501
- Anti-MUC-1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC-1 peptide
- 290463
- (1998) Int J Cancer , vol.76 , Issue.6 , pp. 817-823
- Reddish, M.¹ MacLean, G.D.² Koganty, R.R.³ Kan-Mitchell, J.⁴ Jones, V.⁵ Mitchell, M.S.⁶ Longenecker, B.M.⁷

6
- 0005945027
- Biomira Inc: Annual Report 1997 - Biomira Inc. Annual Report 31 December 295758
- (1997)

7
- 0030000007
- A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma
- 323584
- (1996) J Surg Res , vol.63 , Issue.1 , pp. 298-304
- Goydos, J.S.¹ Elder, E.² Whiteside, T.L.³ Finn, O.J.⁴ Lotze, M.T.⁵

8
- 0005948314
- 335997 Biomira Inc: Biomira begins BLP25 cancer vaccine clinical trial phase II lung cancer trial testing immune response to higher dose/high frequency vaccine treatment. Press release 11 August
- (1999)

9
- 0031914321
- Cancer-associated MUC-1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
- 349891
- (1998) Nature Med , vol.4 , Issue.1 , pp. 43-49
- Agrawal, B.¹ Krantz, M.J.² Reddish, M.A.³ Longenecker, B.M.⁴

10
- 0005987683
- 353448 Biomira Inc: Biomira begins second stage of phase II BLP25 cancer vaccine clinical trial lung cancer trial to test immune response to BLP25 vaccine plus liposomal interleukin-2. Press release 25 January
- (2000)

11
- 0005948315
- 360962 Biomira Inc: Biomira presents new data at Biotechnology Industry Organization meeting. Press release 27 March
- (2000)

12
- 0005949417
- 367712 Biomira Inc: Findings of BLP-25 cancer vaccine combined with dendritic cell therapy presented at American Society of Clinical Oncology Annual Meeting. Press release 22 May
- (2000)

13
- 0005983356
- 367786 Biomira Inc: Data on Biomira's BLP-25 cancer vaccine presented at American Society of Clinical Oncology Annual Meeting. Press release 22 May
- (2000)

14
- 0005909597
- A phase I trial of autologous MUC-1 pulsed dendritic cells for the treatment of patients with relapsed metastasis breast cancer
- 368641 Abs
- (2000) Proc Am Soc Clin Oncol , vol.19 , pp. 1870
- Nussey, F.E.¹ Downing, I.² Waterfall, M.³ Campbell, J.⁴ Hunter, N.R.⁵ Parker, J.⁶ Innes, J.⁷ Samuel, K.⁸ Cook, G.⁹ Turner, M.L.¹⁰ Leonard, R.C.¹¹

15
- 0005949120
- A Phase I study of BrevaRex, a murine monoclonal antibody directed at the MUC-1 antigen in patients with advanced solid tumors
- 368648 Abs
- (2000) Proc Am Soc Clin Oncol , vol.19 , pp. 1868
- Rha, S.Y.¹ Tolcher, A.W.² Stephenson, J.³ Monroe, P.⁴ Eckhardt, G.S.⁵ Hammond, L.A.⁶ Conlon, K.C.⁷ Korz, W.⁸ Von Hoff, D.D.⁹ Rowinsky, E.K.¹⁰

16
- 0005944763
- Phase I study of BLP25 (MUC-1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIb and IV non-small cell lung cancer (NSCLC)
- 368999 Abs
- (2000) Proc Am Soc Clin Oncol , vol.19 , pp. 1824
- Palmer, M.C.¹ Modi, S.² Meikle, A.³ Kehoe, M.⁴ Parker, J.⁵ Butts, C.⁶ Smylie, M.⁷ MacLean, G.⁸ Logenecker, M.⁹

17
- 0005980155
- 378515 Biomira Inc: Biomira initiates phase IIb multi-centre trial with BLP25 vaccine in lung cancer patients: Randomized, controlled study to measure efficacy, optimum dosing. Press release 09 August
- (2000)

18
- 0032127618
- Liposomal formulations of synthetic MUC-1 peptides: Effects of encapsulation versus surface display of peptides on immune responses
- 392736
- (1998) Bioconjug Chem , vol.9 , Issue.4 , pp. 451-458
- Guan, H.H.¹ Budzynski, W.² Koganty, R.R.³ Krantz, M.J.⁴ Reddish, M.A.⁵ Rogers, J.A.⁶ Longenecker, B.M.⁷ Samuel, J.⁸

19
- 0031701743
- Rapid induction of primary human CD4+ and CD8+ T-cell responses against cancer-associated MUC-1 peptide epitopes
- 392749
- (1998) Int Immunol , vol.10 , Issue.12 , pp. 1907-1916
- Agrawal, B.¹ Krantz, M.J.² Reddish, M.A.³ Longenecker, B.M.⁴

20
- 0034075941
- T-cell suppression as a mechanism for tolerance to MUC-1 antigen in MUC-1 transgenic mice
- 395065
- (2000) Breast Cancer Res Treat , vol.60 , Issue.2 , pp. 107-115
- Chen, D.¹ Koido, S.² Li, Y.³ Gendler, S.⁴ Gong, J.⁵

21
- 0032918203
- Cellular and humoral immune responses to MUC-1 mucin and tandem-repeat peptides in ovarian cancer patients and controls
- 395067
- (1999) Cancer Immunol Immunother , vol.48 , Issue.1 , pp. 47-55
- Snijdewint, F.G.¹ von Mensdorff-Pouilly, S.² Karuntu-Wanamarta, A.H.³ Verstraeten, A.A.⁴ van Zanten-Przybysz, I.⁵ Hummel, P.⁶ Nijman, H.W.⁷ Kenemans, P.⁸ Hilgers, J.⁹

22
- 0032925109
- Lack of evidence for an immunosuppressive role for MUC-1
- 395070
- (1999) Cancer Immunol Immunother , vol.48 , Issue.1 , pp. 22-28
- Paul, S.¹ Bizouame, N.² Paul, A.³ Price, M.R.⁴ Hansson, G.C.⁵ Kieny, M.P.⁶ Acres, R.B.⁷

23
- 0033032313
- Specificity analysis of sera from breast cancer patients vaccinated with MUC-1-KLH plus QS-21
- 395080
- (1999) Br J Cancer , vol.79 , pp. 1806-1812
- Adluri, S.¹ Gilewski, T.² Zhang, S.³ Ramnath, V.⁴ Ragupathi, G.⁵ Livingston, P.⁶

24
- 0031765186
- Delivery of MUC-1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T-helper immune responses
- 395085
- (1998) J Pharm Sci , vol.87 , pp. 1421-1427
- Newman, K.D.¹ Sosnowski, D.L.² Kwon, G.S.³ Samuel, J.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.